IONISOS acquired by 3I

Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins. The current management team, led by CEO Thibaut Hyvernat, will remain significantly invested in this new chapter.

Permira, the global private equity firm, successfully completed the acquisition of Cambrex Corporation, a premier small molecule CDMO, in a take-private transaction that signaled a major consolidation move in the pharmaceutical services sector. The transaction was structured as a merger whereby shareholders received $60.00 in cash per share, representing a significant premium of 47.1% over the undisturbed share price. The deal allowed Cambrex to delist from the New York Stock Exchange and transition into a private entity, providing the management team with the long-term capital and operational flexibility required to further integrate its acquisitions and invest in global capacity expansion

Permira acquired a majority stake in Quotient Sciences from GHO Capital, which had owned the business since 2015. Under GHO's four-year ownership, the company underwent a major transformation, expanding its service offering into commercial manufacturing and establishing a significant presence in the United States through strategic investments and acquisitions. The transaction provided GHO with a strong exit while securing new capital for Quotient to continue its international expansion.

Ardian acquired a majority stake in Sintetica from the majority shareholder Daphne and the owner family. The transaction was structured as a partnership, with the existing shareholders and management team reinvesting via a significant minority stake to maintain continuity. At the time of the deal, Sintetica was in a phase of hyper-growth (31% CAGR between 2016-2018). Ardian's investment was designed to accelerate the company's internationalization—expanding its reach beyond the 45 countries it already served—and to fuel R&D for new patented, "ready-to-use" drug delivery systems that optimize hospital efficiency and patient safety

ICG acquired 100% of DOC Generici from CVC Capital Partners, marking the company's third private equity cycle. Merieux Equity Partners joined as a strategic co-investor to leverage its industrial expertise in life sciences. The deal was financed by a syndicate of banks including UniCredit, BNP Paribas, Credit Agricole, and Barclays. The investment thesis was built on DOC's resilient "asset-light" business model, which delivers high margins and strong cash flow conversion. Under ICG's ownership, the group aims to further expand its product pipeline and potentially explore international M&A to diversify its purely Italian revenue base

Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs

The global life sciences leader has finalized the acquisition of 100% of the share capital of the target from a prominent European private equity firm. This strategic transaction represents a definitive move to incorporate advanced digital capabilities into the group’s specialized animal health division, targeting the high-growth segment of animal intelligence and monitoring. The strategic rationale for the move centers on the acquirer's objective to provide integrated, data-driven health management solutions that complement its existing portfolio of vaccines and medicines

Ardian acquired a majority stake in Neopharmed Gentili from its founding parent company, Mediolanum Farmaceutici. The Del Bono family, founders of Mediolanum, retained a 20% minority stake in the business to ensure operational and clinical continuity. The transaction was structured to provide the group with the capital and global network necessary to transition from a national champion to an international specialty pharma platform. The investment thesis centered on using Neopharmed's robust Italian sales network as a foundation for an aggressive "buy-and-build" strategy, targeting both product portfolios and strategic corporate acquisitions across Europe

Ardian acquired a majority stake in Inula from Vendis Capital and founder Dominique Baudoux. The founder and Vendis Capital retained reinvestment options, while the CEO and the management team reinvested significantly to increase their equity stake. The acquisition aimed to leverage Ardian's global footprint to accelerate Inula's expansion in the US, Italy, and Germany, and to pursue buy-and-build opportunities in the fragmented aromatherapy market.

The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth. Astorg Partners' investment in Nemera is expected to support the company's continued growth and expansion, with a focus on driving innovation, improving operational efficiency, and enhancing customer satisfaction